These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28741230)

  • 1. New Therapeutic Strategies for Lewy Body Dementias.
    Velayudhan L; Ffytche D; Ballard C; Aarsland D
    Curr Neurol Neurosci Rep; 2017 Sep; 17(9):68. PubMed ID: 28741230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
    Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
    Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia.
    Gomperts SN
    Continuum (Minneap Minn); 2016 Apr; 22(2 Dementia):435-63. PubMed ID: 27042903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic approaches in Parkinson's disease and related disorders.
    Valera E; Masliah E
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):346-352. PubMed ID: 26749150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
    Jellinger KA; Korczyn AD
    BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical Lewy body disease and Parkinson's disease dementia.
    Burn DJ
    Curr Opin Neurol; 2006 Dec; 19(6):572-9. PubMed ID: 17102696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease.
    Henderson MX; Covell DJ; Chung CH; Pitkin RM; Sandler RM; Decker SC; Riddle DM; Zhang B; Gathagan RJ; James MJ; Trojanowski JQ; Brunden KR; Lee VMY; Luk KC
    Neurobiol Dis; 2020 Mar; 136():104712. PubMed ID: 31837422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lewy Body Dementia.
    Sanford AM
    Clin Geriatr Med; 2018 Nov; 34(4):603-615. PubMed ID: 30336990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral symptomatology and psychopharmacology of Lewy body dementia.
    Tampi RR; Young JJ; Tampi D
    Handb Clin Neurol; 2019; 165():59-70. PubMed ID: 31727230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies.
    Camicioli R; Fisher N
    Can J Neurol Sci; 2004 Feb; 31(1):7-21. PubMed ID: 15038467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.
    Hall H; Reyes S; Landeck N; Bye C; Leanza G; Double K; Thompson L; Halliday G; Kirik D
    Brain; 2014 Sep; 137(Pt 9):2493-508. PubMed ID: 25062696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lewy Body Dementias.
    Armstrong MJ
    Continuum (Minneap Minn); 2019 Feb; 25(1):128-146. PubMed ID: 30707190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies.
    Aarsland D
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S144-8. PubMed ID: 26411499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
    Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
    Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New evidence on the management of Lewy body dementia.
    Taylor JP; McKeith IG; Burn DJ; Boeve BF; Weintraub D; Bamford C; Allan LM; Thomas AJ; O'Brien JT
    Lancet Neurol; 2020 Feb; 19(2):157-169. PubMed ID: 31519472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
    Orimo S
    Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.
    Jellinger KA
    Biochim Biophys Acta; 2009 Jul; 1792(7):730-40. PubMed ID: 18718530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.